Exploring resistance of Plasmodium vivax to antimalarial drugs: A retrospective and prospective study [ 2011 - 2013 ]

Also known as: Why is vivax malaria developing resistance to antimalarial drugs?

Research Grant

[Cite as]

Researchers: Prof Timothy Davis (Principal investigator) ,  Prof Ivo Mueller Prof Peter Siba

Brief description Although previously considered a 'benign' form of the disease, vivax malaria is increasingly recognised as a cause of complications and even death. Unfortunately, the parasite is developing resistance to conventional drugs. Papua New Guinea was where resistance to chloroquine was first detected and other drugs are following suit. We plan to examine the parasite genes involved in this process, including before and after the introduction of a new strategy in PNG, artemisinin combination therapy.

Funding Amount $AUD 439,230.26

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]